A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects

BACKGROUND: The delta opioid receptor (DOR) has been identified as a therapeutic target for migraine, with DOR agonists exhibiting low abuse potential compared with conventional µ-opioid agonists. TRV250 is a novel small molecule agonist of the DOR that is preferentially selective for G-protein sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Fossler, Michael J., Schmith, Virginia, Greene, Stephen A., Lohmer, Lauren, Kramer, Michael S., Arscott, Kelly, James, Ian E., Demitrack, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392943/
https://www.ncbi.nlm.nih.gov/pubmed/32676977
http://dx.doi.org/10.1007/s40263-020-00738-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392943/
https://www.ncbi.nlm.nih.gov/pubmed/32676977
http://dx.doi.org/10.1007/s40263-020-00738-0

Ejemplares similares